Ranbaxy Receives Final Approval for Gabapentin Tablets
16th Sep 2005, 17:35 GMT
Ranbaxy Pharmaceuticals, a wholly owned subsidiary of Ranbaxy Labs, announced that RLL has received approval from the US FDA, Office of Generic Drugs, to manufacture and market Gabapentin Tablets, 600 and 800 mg strengths.
Latest news from FDA News News from myHealthcareNews.com:
- North American Gets Cancer Treatment OK
- North American Scientific Announces FDA Clearance of its ClearPath HDR Breast Brachytherapy System
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ.
- ACT-AD Coalition Calls FDA's New Focus on Neurological Diseases a Positive 1st Step
- Ivax Diagnostics Delays Filing 3Q Report
- New Corporate Members and Leaders for C-Path's Predictive Safety Testing Consortium Announced
- Diagnosoft Receives FDA Approval for Cardiac MRI Quantitative Regional Function Software Based on the HARP Technology
- PAREXEL Consulting Expands Risk Mgmt Expertise, Appoints Former FDA Consumer Safety Officer Raymond T Oji as Senior Consultant
- Trubion Pharmaceuticals to Present at the Lazard Life Sciences Conference
- Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting